BGI Genomics Co., Ltd. (300676.SZ)

BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing; epigenetics whole genome bisulfite sequencing and ChIp-Seq; and metagenomics and 16S/18S/ITS sequencing. It also provides RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing; single cell sequencing and high throughput single cell RNA-Seq; spatial transcriptome-stereo-seq; immune repertoire and pre-made library sequencing; and bioinformatics solutions. In addition, the company offers mass spectrometry, including proteomics, metabolomics, and multi-omics. Further, it provides clinical solutions for reproductive health, oncology, infectious disease, and chronic disease. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.